Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX   US92532F1003

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vertex Pharmaceuticals Inc
Discovers and develops novel, small molecule pharmaceuticals

Vertex Pharmaceuticals, Inc. is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs.

The company's research focuses on cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis.

Its product pipe line includes NCIVEK (telaprevir), which is marketed in the U.S. and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which it markets in the U.S., Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation.

The company's other drug candidates include ivacaftor, VX-809, VX-661, VX-135, VX-222, VX-509 and VX-787.

Vertex Pharmaceuticals was founded by Boger S. Joshua in 1989 and is headquartered in Cambridge, MA.
Sales per Businesses
20122013Delta
USD (in Million)%USD (in Million)%
Pharmaceuticals1,527100%1,212100% -26%
Sales per Regions
20122013Delta
USD (in Million)%USD (in Million)%
United States1,37489.9%896.9574% -53.13%
Europe129.798.5%279.5623.1% +53.57%
Other23.741.6%35.472.9% +33.06%
United Kingdom-----
Managers
NameTitle
Michael PartridgeInvestor Relations
Ian F. SmithChief Financial Officer
Jeffrey LeidenChairman and Chief Executive Officer
Kenneth L. HortonGeneral Secretary
Surperformance© rating of Vertex Pharmaceuticals Inc
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER - - -
Potential
Yield - - -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector
Healthcare
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Biotechnology
Shareholders
- Capital World Investors 10,80%
- Wellington Management Company 7,00%
- Blackrock 6,90%
- The Vanguard Group 6,70%
- Prudential Financial 5,80%
- Managers and Directors 2,30%
- Mister Joshua S. Boger 1,00%
Advertisement
Sector Biotechnology
Trading RatingInvestor Rating
GILEAD SCIENCES, ..
AMGEN, INC.
BIOGEN IDEC INC
CELGENE CORPORATI..
CSL LIMITED
Sector Biotechnology
Company contact information
50 avenue Northern
US-MA 02210 Boston
USA

Phone : +1 617 444 6100
Fax : +1 617 444 6680
Internet : http://www.vpharm.com
Markets and indexes
- NASDAQ All Markets
- Nasdaq Global Select Market
- Nasdaq 100 / SP500
Stock Exchange Codes
- ISIN Code :  US92532F1003
- Bloomberg Code :  VRTX:US
- Reuters Code :  VRTX.O
- Datastream Code :  
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF